VENATORX PHARMACEUTICALS INC

THE PURPOSE OF THIS CONTRACT IS THE DEVELOPMENT OF A NOVEL ORALLY BIOAVAILABLE BETA-LACTAMASE INHIBITOR THROUGH DELIVERY TO THE GOVERNMENT OF: CMC AND PRELIMINARY NON-CLINICAL DEVELOPMENT (CLIN 001); A BETA-LACTAM CLINICAL STUDY (CLIN 002); A NON-GLP

THE PURPOSE OF THIS BILATERAL MODIFICATION DE-OBLIGATES FUNDS FROM REQUISITION OS237567 IN THE AMOUNT OF (-.01) FROM CLIN0001.

NON BETA-LACTAM INHIBITORS OF PENICILLIN BINDING PROTEINS TARGETING MDR-ACINETOBACTER BAUMANNII.

THE PURPOSE OF THIS CONTRACT IS THE DEVELOPMENT OF A NOVEL ORALLY BIOAVAILABLE BETA-LACTAMASE INHIBITOR THROUGH DELIVERY TO THE GOVERNMENT OF: CMC AND PRELIMINARY NON-CLINICAL DEVELOPMENT (CLIN 001); A BETA-LACTAM CLINICAL STUDY (CLIN 002); A NON-GLP

THE PURPOSE OF THIS MODIFICATION IS TO PROVIDE SUPPLEMENTAL FUNDING FOR CLIN0009, UPDATE SECTION G.1 CONTRACTING OFFICER, AND UPDATE ATTACHMENT 1, STATEMENT OF WORK (SOW) DATED 7/31/2024 TO SUPPORT THE ACTIVITIES REQUIRED TO ADDRESS THE FDA?S COMPLET

THE PURPOSE OF THIS CONTRACT IS THE DEVELOPMENT OF A NOVEL ORALLY BIOAVAILABLE BETA-LACTAMASE INHIBITOR THROUGH DELIVERY TO THE GOVERNMENT OF: CMC AND PRELIMINARY NON-CLINICAL DEVELOPMENT (CLIN 001); A BETA-LACTAM CLINICAL STUDY (CLIN 002); A NON-GLP

NON BETA-LACTAM INHIBITORS OF PENICILLIN BINDING PROTEINS TARGETING MDR-ACINETOBACTER BAUMANNII.

VENATORX PHARMACEUTICALS: NEW ANTIBIOTICS TO TREAT DRUG-RESISTANT GRAM-NEGATIVE BACTERIA INCLUDING PUBLIC HEALTH PATHOGENS.

THE PURPOSE OF THIS MODIFICATION IS TO PROVIDE SUPPLEMENTAL FUNDING FOR CLIN0002, AND CLIN0003, EXTEND THE PERIOD OF PERFORMANCE FOR CLIN0002 THROUGH MARCH 31, 2024, EXTEND THE PERIOD OF PERFORMANCE FOR CLIN0003 THROUGH SEPTEMBER 30, 2025, AND INCORP

DEVELOPMENT OF THERAPEUTIC MEDICAL COUNTERMEASURES FOR BIODEFENSE AND EMERGING INFECTIOUS DISEASES

THE PURPOSE OF THIS CONTRACT IS THE DEVELOPMENT OF A NOVEL ORALLY BIOAVAILABLE BETA-LACTAMASE INHIBITOR THROUGH DELIVERY TO THE GOVERNMENT OF: CMC AND PRELIMINARY NON-CLINICAL DEVELOPMENT (CLIN 001); A BETA-LACTAM CLINICAL STUDY (CLIN 002); A NON-GLP

NON BETA-LACTAM INHIBITORS OF PENICILLIN BINDING PROTEINS TARGETING MDR-ACINETOBACTER BAUMANNII.

VENATORX PHARMACEUTICALS: ANTIBIOTIC FOR AMR AND BIOTHREAT PATHOGENS

ADD ADDITIONAL FUNDING TO CLIN 0007, UPDATE PERIOD OF PERFORMANCE, AND ADD IPP LANGUAGE

TO ADVANCE A NOVEL BETA-LACTAMASE INHIBITOR OF PENICILLIN BINDING PROTEINS TARGETING MDR-ACINETOBACTER BAUMANNII.

EXERCISE OPTION 8 CLIN 0009 AND REVISE GOVT COST SHARE AMOUNT

TO ADVANCE A NOVEL BETA-LACTAMASE INHIBITOR OF PENICILLIN BINDING PROTEINS TARGETING MDR-ACINETOBACTER BAUMANNII.